(HealthDay)—For patients with atrial fibrillation (AF), those undergoing ablation have a significantly reduced risk for recurrent AF compared with those receiving drug therapy, regardless of sex, according to a study published in the Feb. 16 issue of Circulation.
Andrea M. Russo, M.D., from Cooper Medical School of Rowan University in Camden, New Jersey, and colleagues examined outcomes for 819 women and 1,385 men with AF ages 65 years and older or aged younger than 65 years with at least one risk factor for stroke. Participants were randomly assigned to either catheter ablation with pulmonary vein isolation or drug therapy with rate/rhythm control agents.
The researchers found that during the index procedure, women were less likely than men to have ancillary ablation procedures performed (55.7 versus 62.2 percent); in both sexes, complications from treatment occurred infrequently. For the primary outcome of death, disabling stroke, serious bleeding, or cardiac arrest, the hazard ratio was 1.01 (95 percent confidence interval, 0.62 to 1.65) for women and 0.73 (95 percent confidence interval, 0.51 to 1.05) for men for ablation versus drug therapy. Compared with those receiving drug therapy, patients undergoing ablation had a significantly reduced risk for recurrent AF, but the effect was greater for men (hazard ratio, 0.48; 95 percent confidence interval, 0.40 to 0.58) than women (hazard ratio, 0.64; 95 percent confidence interval, 0.51 to 0.82).
“When compared with drug therapy, ablation offers comparable benefits for women and men,” the authors write. “Consequently, sex should not be used as a basis for selecting a management strategy for the treatment of AF.”
Several authors disclosed financial ties to pharmaceutical and medical device companies, some of which funded the study.
Ablation cuts risk of recurrent stroke in patients with A-fib
Abstract/Full Text (subscription or payment may be required)
Copyright © 2020 HealthDay. All rights reserved.
Ablation beats drug therapy for women and men with A-fib (2021, February 16)
retrieved 16 February 2021
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.
- COVID case rates hit new high for England, study finds - April 7, 2022
- Govt’s focus on affordable healthcare ensured significant savings for poor, middle class: PM Modi - April 7, 2022
- SRL Diagnostics and Skye Air Mobility collaborate to transport pathology samples using drone logistics - April 6, 2022
- Healthineers sets up new production line of CT scanners in Bengaluru under PLI scheme - April 6, 2022
- Lupin inks licensing pact with Alvion to market drugs in Southeast Asia - April 6, 2022
- Yoga Mahotsav: Ayush Ministry to organise event to demonstrate common yoga on World Health Day - April 6, 2022
- LordsMed forays into the medtech space with launch of health ATMs ‘Lords Sehat’ - April 5, 2022
- ‘Friendly viruses’ can be the next big thing in the history of medical research and more - April 5, 2022
- No setback to Bharat Biotech even as WHO suspends Covaxin UN supply: Sources - April 4, 2022
- Govt panel recommends Serum’s Covovax dose for kids aged 12 and above - April 4, 2022